ClinicalTrials.gg
CompletedNCT01397786ZENITHUpdated May 10, 2017Results posted

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

A Phase 3 interventional study of OPC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 148 sites in 19 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-10.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,044
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
Largest of 28
1,044 · median 155
Started
2011
with 6 others
Phase 3
16 of 28
none open now
Registered
5th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one has the largest enrollment, is one of 7 that started in 2011, is one of 16 in phase 3, and was the 5th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia.

Read the detailed description

Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by criteria
  2. Outpatient status at last visit of Trial 331-10-230 or Trial 331-10-231
  3. Willing to discontinue all prohibitive psychotropic medications to meet protocol required washouts prior to and during the trial period.
  4. Other protocol specific inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  1. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
  2. Subjects with a current Axis I diagnosis of:

    • Schizoaffective disorder
    • MDD
    • Bipolar disorder
    • Delirium, dementia, amnestic or other cognitive disorder
    • Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder
  3. Subjects presenting with a first episode of schizophrenia
  4. Other protocol specific exclusion criteria may apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,044 participants (actual)

Study arms

  • Experimental
    OPC-34712

    Drug: OPC-34712

Interventions

  • Phase A: 1-2 mgs/day by mouth, max of 4 wks. Phase B: 1-4 mgs/day by mouth, up to 52 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption or reduction of IMP.

    Time frame: From Baseline up to 52 Weeks

Secondary outcomes

  1. Mean Change From Baseline in Positive and Negative Syndrome Scale Total Score

    The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS total score was sum of rating scores for 7 positive, 7 negative, and 16 general psychopathology subscale items of PANSS panel.

    Time frame: From Baseline up to 52 Weeks

  2. Mean Change From Baseline in PANSS Positive Subscale Score

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.

    Time frame: From Baseline up to 52 Weeks

  3. Mean Change From Baseline in PANSS Negative Subscale Score

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking.

    Time frame: From Baseline up to 52 Weeks

  4. Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale Score

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: From Baseline up to 52 Weeks

  5. Mean Change From Baseline in Personal and Social Performance Scale Total Score

    The PSP was a validated clinician-rated scale that measured personal and social functioning in four domains: socially useful activities (e.g, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment that determined the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

    Time frame: From Baseline up to 52 Weeks

  6. Mean Clinical Global Impression - Improvement Score

    The efficacy of study medication was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due to the drug treatment. All responses were compared to the participant's condition at Screening/Baseline (i.e, Week 6 visit of Protocol NCT00905307). Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: From Baseline up to 52 Weeks

  7. Response Rate

    Response rate was defined as a reduction of ≥ 30% from Baseline in PANSS total score or CGI-I score of 1 (very much improved) or 2 (much improved) at the Last Visit.

    Time frame: From Baseline up to 52 Weeks

  8. Discontinuation Rate for Lack of Efficacy

    Discontinuation rate for the participants who discontinued due to lack of efficacy were examined.

    Time frame: From Baseline up to 52 Weeks

  9. Mean Change From Baseline in Positive and Negative Syndrome Scale Excited Component Score

    The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).

    Time frame: From Baseline up to 52 Weeks

  10. Mean Change From Baseline in PANSS Marder Factor Scores - Positive Symptoms Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score was the sum of the 8 components (delusions (P1), hallucinatory behavior (P3), grandiosity (P5), suspiciousness/persecution (P6), stereotyped thinking (N7), somatic concern (G1), unusual thought content (G9) and lack of judgment and insight (G12)) of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Time frame: From Baseline up to 52 Weeks

  11. Mean Change From Baseline in PANSS Marder Factor Scores - Negative Symptoms Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items (blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity and conversation flow (N6), motor retardation (G7) and active social avoidance (G16)) of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Time frame: From Baseline up to 52 Weeks

  12. Mean Change From Baseline in PANSS Marder Factor Scores - Disorganized Thought Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items (conceptual disorganization (P2), difficulty in abstract thinking (N5), mannerisms and posturing (G5), disorientation (G10), poor attention (G11), disturbance of volition (G13) and preoccupation (G15)) on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).

    Time frame: From Baseline up to 52 Weeks

  13. Mean Change From Baseline in PANSS Marder Factor Scores - Hostility/ Excitement Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items (excitement (P4), hostility (P7), uncooperativeness (G8) and poor impulse control (G14)) on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Time frame: From Baseline up to 52 Weeks

  14. Mean Change From Baseline in PANSS Marder Factor Scores - Anxiety/Depression Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items (anxiety (G2), guilt feelings (G3), tension (G4) and depression (G6)) on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Time frame: From Baseline up to 52 Weeks

07

Results

Posted Mar 27, 2017

Participant flow

This trial was conducted in a total of 1072 participants (1044 of whom entered the open-label treatment phase) at 202 trial sites in the following 18 countries: Japan, Korea, Malaysia, Philippines, Taiwan, Croatia, Latvia, Poland, Romania, Russia, Serbia, Turkey, Ukraine, Columbia, Mexico, Canada, Puerto Rico, and United States of America (USA).

Phase A
Participant flow — Phase A
MilestonePrior BrexpiprazolePrior PlaceboDe Novo
Started120227
Completed120199
Not completed0028
Withdrew: Lost to follow-up006
Withdrew: Adverse event008
Withdrew: Subject met withdrawal criteria007
Withdrew: Physician decision001
Withdrew: Withdrawal by subject005
Withdrew: Lack of efficacy001
Phase B
Participant flow — Phase B
MilestonePrior BrexpiprazolePrior PlaceboDe Novo
Started611204229
Completed30810991
Not completed30395138
Withdrew: Lost to follow-up221222
Withdrew: Adverse event1092327
Withdrew: Subject met withdrawal criteria38538
Withdrew: Physician decision913
Withdrew: Withdrawal by subject1024530
Withdrew: Protocol deviation124
Withdrew: Lack of efficacy22714

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs)

A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption or reduction of IMP.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsPrior BrexpiprazolePrior PlaceboDe NovoTotal
With AEs60.256.465.260.5
With TEAEs60.056.465.260.4
With SAEs14.98.911.212.9
SecondaryMean Change From Baseline in Positive and Negative Syndrome Scale Total Score

The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS total score was sum of rating scores for 7 positive, 7 negative, and 16 general psychopathology subscale items of PANSS panel.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Positive and Negative Syndrome Scale Total Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=375,134,123,632)-6.90 ± 12.90-12.50 ± 14.90-6.60 ± 13.60-8.00 ± 13.60
At Week 52 (Participant count= 226,93,91,410)-11.0 ± 14.40-18.40 ± 16.90-8.80 ± 12.60-12.20 ± 15.00
At Last Visit (Participant count=591,198,223,1012)-3.80 ± 16.70-9.70 ± 18.70-3.50 ± 14.30-4.90 ± 16.80
SecondaryMean Change From Baseline in PANSS Positive Subscale Score

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Positive Subscale Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=375,134,123,632)-2.10 ± 4.50-4.10 ± 5.40-1.70 ± 4.30-2.40 ± 4.70
At Week 52 (Participant count=226,93,91,410)-3.20 ± 4.60-5.80 ± 5.20-2.30 ± 4.10-3.60 ± 4.80
At Last Visit (Participant count=591,198,223,1012)-0.90 ± 5.90-2.80 ± 6.40-1.00 ± 4.90-1.30 ± 5.80
SecondaryMean Change From Baseline in PANSS Negative Subscale Score

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Negative Subscale Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=375,134,123,632)-1.40 ± 3.70-2.40 ± 4.30-1.30 ± 3.80-1.60 ± 3.90
At Week 52 (Participant count=226,93,91,410)-2.70 ± 4.50-3.70 ± 5.40-2.00 ± 3.70-2.80 ± 4.60
At Last Visit (Participant count=591,198,223,1012)-1.00 ± 4.10-2.40 ± 5.00-0.60 ± 4.20-1.20 ± 4.30
SecondaryMean Change From Baseline in Clinical Global Impression - Severity of Illness Scale Score

The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At at Week 26 (Participant count=375,134,123,632)-0.35 ± 0.79-0.60 ± 0.98-0.24 ± 0.88-0.38 ± 0.86
At Week 52 (Participant count=226,93,91,410)-0.55 ± 0.86-0.97 ± 0.98-0.48 ± 0.86-0.63 ± 0.91
At Last Visit (Participant count=591,198,223,1012)-0.14 ± 1.04-0.46 ± 1.12-0.17 ± 0.88-0.21 ± 1.03
SecondaryMean Change From Baseline in Personal and Social Performance Scale Total Score

The PSP was a validated clinician-rated scale that measured personal and social functioning in four domains: socially useful activities (e.g, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment that determined the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Personal and Social Performance Scale Total Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=366,134,123,623)4.50 ± 9.706.50 ± 11.304.50 ± 9.004.90 ± 10.00
At Week 52 (Participant count=223,93,91,407)7.00 ± 10.609.60 ± 11.907.60 ± 10.807.70 ± 11.00
At Last Visit (Participant count=569,196,219,984)1.80 ± 12.405.10 ± 12.802.70 ± 11.002.70 ± 12.20
SecondaryMean Clinical Global Impression - Improvement Score

The efficacy of study medication was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due to the drug treatment. All responses were compared to the participant's condition at Screening/Baseline (i.e, Week 6 visit of Protocol NCT00905307). Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression - Improvement Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=381,134,123,638)3.00 ± 1.132.77 ± 0.993.00 ± 1.132.95 ± 1.10
At Week 52 (Participant count=226,93,91,410)2.66 ± 1.132.26 ± 0.972.76 ± 1.092.59 ± 1.10
At Last Visit (Participant count=598,198,223,1019)3.31 ± 1.432.96 ± 1.333.30 ± 1.273.24 ± 1.38
SecondaryResponse Rate

Response rate was defined as a reduction of ≥ 30% from Baseline in PANSS total score or CGI-I score of 1 (very much improved) or 2 (much improved) at the Last Visit.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Number · percentage of participants
Response Rate
percentage of participantsPrior BrexpiprazolePrior PlaceboDe NovoTotal
Response Rate34.242.627.234.3
SecondaryDiscontinuation Rate for Lack of Efficacy

Discontinuation rate for the participants who discontinued due to lack of efficacy were examined.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Number · percentage of participants
Discontinuation Rate for Lack of Efficacy
percentage of participantsPrior BrexpiprazolePrior PlaceboDe NovoTotal
Discontinuation Rate for Lack of Efficacy3.63.56.34.2
SecondaryMean Change From Baseline in Positive and Negative Syndrome Scale Excited Component Score

The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Positive and Negative Syndrome Scale Excited Component Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=375,134,123,632)-0.60 ± 3.10-1.80 ± 3.70-0.70 ± 3.10-0.90 ± 3.30
At Week 52 (Participant count=226,93,91,410)-1.20 ± 3.20-2.60 ± 3.40-1.00 ± 2.90-1.50 ± 3.20
At Last Visit (Participant count=591,198,223,1012)0.10 ± 4.10-0.90 ± 4.20-0.30 ± 3.50-0.20 ± 4.00
SecondaryMean Change From Baseline in PANSS Marder Factor Scores - Positive Symptoms Score

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score was the sum of the 8 components (delusions (P1), hallucinatory behavior (P3), grandiosity (P5), suspiciousness/persecution (P6), stereotyped thinking (N7), somatic concern (G1), unusual thought content (G9) and lack of judgment and insight (G12)) of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores - Positive Symptoms Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=375,134,123,632)-2.60 ± 4.80-4.70 ± 5.50-2.00 ± 5.20-2.90 ± 5.10
At Week 52 (Participant count=226,93,91,410)-3.90 ± 5.20-6.60 ± 5.70-2.60 ± 4.80-4.20 ± 5.40
At Last Visit (Participant count=591,198,223,1012)-1.60 ± 5.90-3.50 ± 6.50-1.30 ± 5.00-1.90 ± 5.90
SecondaryMean Change From Baseline in PANSS Marder Factor Scores - Negative Symptoms Score

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items (blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity and conversation flow (N6), motor retardation (G7) and active social avoidance (G16)) of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores - Negative Symptoms Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=375,134,123,632)-1.50 ± 3.60-2.20 ± 4.00-1.70 ± 4.10-1.70 ± 3.80
At Week 52 (Participant count=226,93,91,410)-2.60 ± 4.30-3.90 ± 5.00-2.20 ± 3.80-2.80 ± 4.40
At Last Visit (Participant count=591,198,223,1012)-1.00 ± 4.10-2.30 ± 5.10-0.70 ± 4.10-1.20 ± 4.40
SecondaryMean Change From Baseline in PANSS Marder Factor Scores - Disorganized Thought Score

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items (conceptual disorganization (P2), difficulty in abstract thinking (N5), mannerisms and posturing (G5), disorientation (G10), poor attention (G11), disturbance of volition (G13) and preoccupation (G15)) on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores - Disorganized Thought Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=375,134,123,632)-1.70 ± 3.30-2.60 ± 3.50-1.70 ± 3.50-1.90 ± 3.40
At Week 52 (Participant count=226,93,91,410)-2.90 ± 3.70-3.70 ± 4.60-2.30 ± 3.70-2.90 ± 4.00
At Last Visit (Participant count=591,198,223,1012)-1.20 ± 4.20-2.20 ± 4.50-0.90 ± 4.00-1.40 ± 4.20
SecondaryMean Change From Baseline in PANSS Marder Factor Scores - Hostility/ Excitement Score

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items (excitement (P4), hostility (P7), uncooperativeness (G8) and poor impulse control (G14)) on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores - Hostility/ Excitement Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=375,134,123,632)-0.40 ± 2.70-1.40 ± 3.10-0.60 ± 2.60-0.60 ± 2.80
At Week 52 (Participant count=226,93,91,410)-0.80 ± 2.70-1.90 ± 2.90-0.90 ± 2.30-1.10 ± 2.70
At Last Visit (Participant count=591,198,223,1012)0.20 ± 3.40-0.70 ± 3.50-0.30 ± 3.00-0.10 ± 3.40
SecondaryMean Change From Baseline in PANSS Marder Factor Scores - Anxiety/Depression Score

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items (anxiety (G2), guilt feelings (G3), tension (G4) and depression (G6)) on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

Time frame:
From Baseline up to 52 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores - Anxiety/Depression Score
Units on a scalePrior BrexpiprazolePrior PlaceboDe NovoTotal
At Week 26 (Participant count=375,134,123,632)-0.70 ± 2.60-1.50 ± 3.00-0.70 ± 3.40-0.90 ± 2.90
At Week 52 (Participant count=226,93,91,410)-0.90 ± 2.50-2.40 ± 2.90-0.80 ± 3.50-1.20 ± 2.90
At Last Visit (Participant count=591,198,223,1012)-0.20 ± 3.20-0.90 ± 3.40-0.40 ± 3.80-0.40 ± 3.40

Adverse events

Collected over The trial required that participants be actively monitored for AEs up to 30 (+2) days after the last dose of study drug, up to 52 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
De Novo (Phase A)—4/226 (1.8%)0/226 (0%)
Prior Brexpiprazole (Phase B)—90/605 (14.9%)166/605 (27.4%)
Prior Placebo (Phase B)—18/202 (8.9%)53/202 (26.2%)
De Novo (Phase B)—25/224 (11.2%)95/256 (37.1%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventDe Novo (Phase A)Prior Brexpiprazole (Phase B)Prior Placebo (Phase B)De Novo (Phase B)
SchizophreniaPsychiatric disorders2/22668/60512/20210/224
Psychotic disorderPsychiatric disorders1/2267/6053/2024/224
AnxietyPsychiatric disorders0/2260/6050/2022/224
Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2260/6051/2020/224
Schizophrenia, Paranoid typePsychiatric disorders0/2261/6051/2020/224
Completed suicidePsychiatric disorders0/2260/6051/2020/224
Emotional disorderPsychiatric disorders0/2260/6051/2020/224
Cardiac failure congestiveCardiac disorders0/2260/6050/2021/224
Coronary artery diseaseCardiac disorders0/2260/6050/2021/224
Abdominal herniaGastrointestinal disorders0/2260/6050/2021/224
Most frequent other events
Most frequent other events
EventDe Novo (Phase A)Prior Brexpiprazole (Phase B)Prior Placebo (Phase B)De Novo (Phase B)
InsomniaPsychiatric disorders0/22651/60517/20232/256
HeadacheNervous system disorders0/22642/60514/20224/256
Weight increasedInvestigations0/22647/60515/20223/256
AgitationPsychiatric disorders0/22630/6057/20223/256
HypertensionVascular disorders0/22610/6052/20220/256
AkathisiaNervous system disorders0/22622/60514/20214/256

Baseline characteristics

Age, Continuous
Age, Continuous(participants)Prior BrexpiprazolePrior PlaceboDe NovoTotal
Mean38.5 ± 10.839.6 ± 10.844.1 ± 11.140.0 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Prior BrexpiprazolePrior PlaceboDe NovoTotal
Female2457985409
Male366125172663
08

Study locations

148 sites
  • Birmingham, Alabama 35226, United States
  • Little Rock, Arkansas 72201, United States
  • Little Rock, Arkansas 72205, United States
  • Springdale, Arkansas 72764, United States
  • Anaheim, California 92805, United States
  • Cerritos, California 90703, United States
  • Escondido, California 92025, United States
  • Garden Grove, California 92845, United States
  • Glendale, California 91206, United States
  • Long Beach, California 90813, United States
  • National City, California 91950, United States
  • Oakland, California 94612, United States
  • Oceanside, California 92056, United States
  • Pico Rivera, California 90660, United States
  • San Diego, California 92102, United States
  • San Diego, California 92103, United States
  • San Diego, California 92123, United States
  • Torrance, California 90502, United States
  • Washington, District of Columbia 20016, United States
  • Bradenton, Florida 34208, United States
  • LeesBurg, Florida 34748, United States
  • Maitland, Florida 32751, United States
  • Miami Springs, Florida 33166, United States
  • Miami, Florida 33143, United States
  • North Miami, Florida 33162, United States
  • Tampa, Florida 33613, United States
  • Chicago, Illinois 60611, United States
  • Hoffman Estates, Illinois 60169, United States
  • Joliet, Illinois 60435, United States
  • Oak Brook, Illinois 60523, United States
  • Overland Park, Kansas 66212, United States
  • Lake Charles, Louisiana 70629, United States
  • Shreveport, Louisiana 71104, United States
  • Flowood, Mississippi 39232, United States
  • St. Charles, Missouri 63301, United States
  • St. Louis, Missouri 63109, United States
  • St. Louis, Missouri 63141, United States
  • Las Vegas, Nevada 89102, United States
  • Buffalo, New York 14215, United States
  • Cedarhurst, New York 11516, United States
  • Jamaica, New York 11432, United States
  • Rochester, New York 14618, United States
  • Staten Island, New York 10305, United States
  • Staten Island, New York 10312, United States
  • Dayton, Ohio 45417, United States
  • Allentown, Pennsylvania 18104, United States
  • Norristown, Pennsylvania 19403, United States
  • Charleston, South Carolina 29407, United States
  • Memphis, Tennessee 38119, United States
  • Austin, Texas 78731, United States
  • Austin, Texas 78754, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75243, United States
  • Houston, Texas 77007, United States
  • Richmond, Virginia 23230, United States
  • Kirkland, Washington 98033, United States
  • Burlington, Ontario L7R 4E2, Canada
  • Chatham, Ontario N7M 5L9, Canada
  • Barranquilla, 00000, Colombia
  • Bello, 00000, Colombia
  • Bogota, 00000, Colombia
  • Pereira, 00000, Colombia
  • Rijeka, 51000, Croatia
  • Zagreb, 10090, Croatia
  • Fujisawa-shi, Kanagawa-Ken 251-8530, Japan
  • Kumamoto-shi, Kumamoto-Ken 861-8002, Japan
  • Kunigami-gun, Okinawa-Ken 904-1201, Japan
  • Sakai-shi, Osaka-Fu 590-0018, Japan
  • Incheon, 400-711, Korea, Republic of
  • Incheon, 405-760, Korea, Republic of
  • Seoul, 136-705, Korea, Republic of
  • Seoul, 137-710, Korea, Republic of
  • Seoul, 143-711, Korea, Republic of
  • Daugavpils, LV-5417, Latvia
  • Jelgava, LV-3008, Latvia
  • Liepaja, LV-3401, Latvia
  • Riga, LV-1005, Latvia
  • Strenci, LV-4730, Latvia
  • Kota Bahru, Kelantan 15586, Malaysia
  • Kajang, Selangor 43000, Malaysia
  • Ipoh, 31250, Malaysia
  • Jalan Greentown, 30450, Malaysia
  • Kuala Lumpur, 59100, Malaysia
  • Sabah, 88815, Malaysia
  • Col. Florida, Distrito Federal 01030, Mexico
  • Monterrey, Nuevo Leon 64060, Mexico
  • San Luis Potosi, San Luis Potos 78218, Mexico
  • Cebu City, 6000, Philippines
  • Davao City, 8000, Philippines
  • Manila, 1000, Philippines
  • Choroszcz, 16-070, Poland
  • Gdansk, 80-282, Poland
  • Gdansk, 80-952, Poland
  • Lodz, 91-229, Poland
  • San Juan, 00918, Puerto Rico
  • San Juan, 00927, Puerto Rico
  • Arad, 310022, Romania
  • Brasov, 500123, Romania
  • Bucuresti, 010825, Romania
  • Bucuresti, 030442, Romania

Showing the first 100 of 148 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793. PubMed 35235720 ↗
  • Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan. PubMed 34901863 ↗
  • Newcomer JW, Eriksson H, Zhang P, Weiller E, Weiss C. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Curr Med Res Opin. 2018 Dec;34(12):2197-2205. doi: 10.1080/03007995.2018.1498779. Epub 2018 Jul 27. PubMed 29985680 ↗
  • Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia. Int J Neuropsychopharmacol. 2018 May 1;21(5):433-441. doi: 10.1093/ijnp/pyy002. PubMed 29415258 ↗
  • Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Correll CU. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016 Jul;174(1-3):93-98. doi: 10.1016/j.schres.2016.04.013. Epub 2016 May 14. PubMed 27188270 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2011
First posted
Jul 20, 2011
Start
Sep 2011
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results first posted
Mar 27, 2017
Last update
May 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01397786
Responsible party
Sponsor
First posted
Jul 20, 2011
Start date
Sep 2011
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Mar 27, 2017
Last update
May 10, 2017

Study contacts

Aleksandar Skuban, M.D.
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion